
















1994Bilateral low systolic toe pressure and toe-brachial index
are associated with long-term mortality in patients with
peripheral artery diseaseJan-Erik Wickström, MD,a Juha Virtanen, MD,a Ellinoora Aro, MD, PhD,b Juho Jalkanen, MD, PhD,a
Maarit Venermo, MD,b and Harri Hakovirta, MD, PhD,a Turku and Helsinki, FinlandABSTRACT
Objective: Based on our previous reports, ipsilateral systolic toe pressure (STP) and toe-brachial index (TBI) have a strong
association with midterm cardiovascular and overall mortality as well as with amputation-free survival in patients with
symptomatic lower extremity peripheral artery disease (PAD). The effect of the often overlooked contralateral lower limb
on patient outcome remains unknown. This study aimed to resolve the significance of contralateral STP (CL_STP) and
contralateral TBI for long-term overall and cardiovascular mortality.
Methods: This is a retrospective cohort study of 727 consecutive patients with symptomatic lower extremity PAD. All
patients admitted to the Department of Vascular Surgery at Turku University Hospital for digital subtraction angiography
between January 2009 and August 2011 and for whom STP measurements were available were recruited and observed
for up to 7 years. Dates and causes of death were collected from the national cause of death registry of Statistics Finland.
Results: In the study cohort, STP was <30 mm Hg in 67 contralateral limbs and 227 ipsilateral limbs. CL_STP <30 mm Hg
resulted in a 60-month estimated freedom from cardiovascular death and overall survival of 39% (standard deviation
[SD], 0.57) and 25% (SD, 0.41), respectively, and contralateral TBI <0.25, of 45% (SD, 0.54) and 36% (SD, 0.54), respectively.
Cumulative freedom from cardiovascular death and overall survival at 60 months for patients with ipsilateral
STP <30 mm Hg varied by CL_STP as follows: CL_STP <30 mm Hg: 41% (SD, 0.58) and 25% (SD, 0.43); CL_STP of 30 to
49 mm Hg: 56% (SD, 0.49) and 44% (SD, 0.49); STP $50 mm Hg: 62% (SD, 0.52) and 47% (SD, 0.52), respectively. In Cox
regression analysis, low STP or TBI of either extremity was associated with significant (P < .001) risk of death for cardio-
vascular or any reason.
Conclusions: Low STP and TBI of both contralateral and ipsilateral lower extremities are associated with high cardio-
vascular and overall mortality in symptomatic PAD patients. Bilaterally low STP and TBI are associated with a particularly
poor prognosis. (J Vasc Surg 2019;70:1994-2004.)
Keywords: Contralateral lower extremity; Toe pressure; Toe-brachial index; Mortality; Peripheral artery diseaseAtherosclerosis is the most frequent single cause of
death in Western countries. Atherosclerotic disease can
be localized into three major vascular beds: cardiac, cere-
bral, and the extremities. Peripheral artery disease (PAD)
is associated with a significant burden of atherosclerosis
in cardiac vessels and cerebral circulation.1 The signifi-
cance of PAD in low-income countries is increasing.2,3
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doi.org/10.1016/j.jvs.2019.03.073have PAD.4 Both symptomatic and asymptomatic PAD
patients have a threefold risk of death and other adverse
cardiovascular events compared with people without
the disease.5-7 Patients with asymptomatic low ankle-
brachial index (ABI < 0.9) are at increased risk for cardio-
vascular events, and chronic limb-threatening ischemia
(CLTI) further increases the risk of limb loss, adverse car-
diovascular events, and death, with myocardial infarction
and ischemic stroke accounting for the majority of car-
diovascular deaths.8-11 Short-term andmidtermmortality
in patients with CLTI is known to be up to four times
higher than in patients with intermittent claudication.12,13
In a clinical setting, peripheral pressure
measurementsdsystolic ankle pressure (SAP), ABI, sys-
tolic toe pressure (STP), and toe-brachial index (TBI)d
are widely used for evaluation of the patient and
clinical decision-making. The European Society of
Cardiology and European Society for Vascular Surgery
guidelines on the diagnosis and treatment of PAD
recommend ABI as a first-line test for screening and
diagnosis of PAD.14 The prognostic value of ABI is well
established and associated with mortality in a U-shaped
manner, with both low and abnormally high (>1.3)






d Type of Research: Single-center retrospective cohort
study
d Key Findings: Bilaterally low systolic toe pressure
(STP) and toe-brachial index (TBI) were associated
with high cardiovascular and overall mortality in
727 peripheral artery disease patients. Freedom
from cardiovascular death at 60 months was 39%
(standard deviation, 0.57) and overall survival 25%
(standard deviation, 0.41) in patients with contralat-
eral STP <30 mm Hg.
d Take Home Message: STP and TBI of lower extrem-
ities may be used for risk assessment in peripheral
artery disease patients. Those with bilaterally low
STP and TBI are at high risk of death.
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Volume 70, Number 6arterial stiffening and incompressibility related to dia-
betes, chronic kidney disease, and high age are the
main culprits for this nonlinear association.15-18 Signifi-
cant stiffening of the digital arteries is rare, and TBI and
STP are often measured in conjunction with SAP and
ABI. As an independent clinical workup, STP is an inex-
pensive, readily available first-line measurement for eval-
uation of PAD with a small interobserver variability and
sufficient reproducibility.19-22 Nevertheless, toe pressures
are not available for patients with extensive tissue loss
in the foot, and toes may have previously been ampu-
tated. In diabetics, first and second toe pressures have
been shown to be comparable, though, so that an ampu-
tated great toe does not necessarily preclude a valid STP
measurement.23 Although TBI has been shown to be
associated with mortality, its relevant threshold values
are not clearly established.24,25
STP of the clinically symptomatic or ipsilateral lower
extremity has recently been shown to be associated
with short-term to midterm cardiovascular mortality,
overall mortality, and amputation-free survival.26,27 As
associations of systolic pressure and pressure indices of
the contralateral lower extremity with survival have not
been studied earlier, we aimed to evaluate the signifi-
cance of contralateral STP (CL_STP) and contralateral
TBI (CL_TBI) for patient outcome.STP either side
(n=727)
CL_STP (n=727) IP_STP (n=699)
Unilateral transmetatarsal
or high amputaon (n=28)
amputaons (n=5)
Fig 1. Flow chart for the study. There were 887 patients
who entered the study; any peripheral pressure measure-
ments were available for 732 patients, unilateral systolic
toe pressure (STP) for 699 patients, and bilateral STP for
727 patients. Extremities with no toes were assigned as
ipsilateral. CL, Contralateral; DSA, digital subtraction angi-
ography; IP, ipsilateral.METHODS
Study cohort. Turku University Hospital serves as a pri-
mary referral center for 477,000 and as a tertiary referral
center for 870,000 inhabitants. During recruitment
between January 2009 and August 2011, there were
887 symptomatic (Rutherford category 2-6) patients
with acute or chronic onset of PAD symptoms referred
to the Department of Vascular Surgery who underwent
digital subtraction angiography (DSA). Patients were
included in the study irrespective of earlier PAD history
or any previous interventions. All patients were retro-
spectively reviewed. Standardized peripheral pressure
measurements were not available for urgent cases
outside office hours. Acutely presenting patients with
thromboembolic arterial obstruction were thus
excluded from the study. A significant number of
patients had bilateral CLTI with clinically indistinguish-
able severity between limbs. Thus, the extremity with
the lowest or no measurable STP was defined as the ipsi-
lateral extremity, and the extremity with the highest STP
was defined as the contralateral extremity. The study
protocol was approved by the local ethical committee
of the Hospital District of Southwest Finland. Because
of the retrospective nature of the study, patient consent
was not required.
Vascular laboratory. Standardized noninvasive hemo-
dynamic measurements were carried out by vascular
technicians at the Turku University Hospital VascularLaboratory. A Nicolet VasoGuard (Nicolet Vascular Inc,
Madison, Wisc) photoplethysmography device was used
for all measurements. Measurements were obtained
from supine patients with preheated feet at heart level.
When stable signals were obtained, brachial, ankle, and
digital cuffs were inflated until disappearance of the
photoplethysmography signal or up to 250 mm Hg.
Brachial, ankle, and toe pressures were determined by
gradual deflation of the cuffs to the moment of reap-
pearance of a pulsatile signal. Toe pressure was preferen-
tially measured from the great toe or from the nearest
available toe.
Table I. Demographics of patient cohort (727 patients) by contralateral systolic toe pressure (CL_STP) categories
CL_STP
P valuea<30 mm Hg 30-49 mm Hg $50 mm Hg
Age, years 75.5 (11) 75.6 (11) 74.7 (10) .622
Female sex 26 (39) 52 (40) 224 (42) .783
CAD 33 (49) 58 (44) 221 (42) .357
CVD 11 (16) 17 (13) 95 (18) .405
HT 47 (70) 98 (75) 361 (68) .540
DM 38 (57) 58 (44) 202 (38) .011
COPD 6 (9.0) 14 (11) 72 (14) .495
Sleep apnea 5 (7.5) 10 (7.6) 29 (5.5) .499
Renal dysfunction 8 (12) 13 (9.9) 49 (9.3) .728
Statin use 21 (31) 48 (37) 200 (38) .600
Antithrombotic 42 (69) 87 (66) 380 (72) .401
Anticoagulation 16 (24) 31 (24) 114 (22) .651
Smoking history 10 (15) 31 (24) 171 (32) .003
Conservative 22 (33) 26 (20) 81 (15) .003
Endovascular 36 (54) 73 (56) 325 (61) .267
Surgery 21 (31) 56 (43) 195 (37) .258
CL_ABI 0.884 (0.80) 0.940 (0.65) 1.04 (0.51) .050
CL_STP 15.3 (11) 39.4 (8.8) 82 (24) <.001
IP_ABI 0.694 (0.76) 0.688 (0.65) 0.756 (0.58) .439
IP_STP 11.9 (11) 27.0 (14) 48.4 (23.9) <.001
No. of cases 67 131 529
CAD, Coronary artery disease; CL_ABI, contralateral ankle-brachial index; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease;
DM, diabetes; HT, hypertension; IP_ABI, ipsilateral ankle-brachial index; IP_STP, ipsilateral systolic toe pressure.
Categorical variables are presented as number (%). Continuous variables are presented as mean (standard deviation). Subsequent treatment mo-
dalities (endovascular, open surgical): percentage receiving one or more revascularizations of given type during follow-up. Mean (standard deviation)
of ABI and STP is shown in addition to baseline medication and medical conditions.
aFisher exact test.
Table II. Causes of death by contralateral systolic toe pressure (CL_STP) categories
Cause of deatha
CL_STP
Total P valueb<30 mm Hg 30-49 mm Hg $50 mm Hg
Cardiovascular 35 (71) 50 (64) 125 (57) 210 (61) <.001
Malignant disease 3 (6.1) 9 (12) 39 (18) 51 (15) .832
Endocrine 1 (2.0) 7 (9.0) 12 (5.5) 20 (5.8) .138
Dementia 4 (8.1) 3 (3.8) 6 (2.7) 13 (3.7) .020
Gastroenterologic 2 (4.1) 4 (5.1) 10 (4.5) 16 (4.6) .532
Miscellaneous 1 (2.0) 1 (1.3) 5 (2.3) 7 (2.0) .456
Accident or violent 1 (2.0) 3 (3.8) 8 (3.6) 12 (3.5) .705
Pulmonary 0 (0.0) 1 (1.3) 6 (2.7) 7 (2.0) 1.000
Urologic 1 (2.0) 0 (0.0) 3 (1.4) 4 (1.2) .442
Alcohol 0 (0.0) 0 (0.0) 3 (1.4) 3 (0.9) 1.000
Neurologic 1 (2.0) 0 (0.0) 1 (0.5) 2 (0.6) .208
Not available 0 (0.0) 0 (0.0) 2 (0.90) 2 (0.6) 1.000
Total 67 131 529 727
Values are reported as number (%).
aAccording to Statistics Finland.
bFisher exact test.
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Fig 2. Kaplan-Meier survival curves showing freedom from cardiovascular death (A) and overall survival (B) by
contralateral systolic toe pressure (CL_STP) and freedom from cardiovascular death (C) and overall survival (D) by
ipsilateral systolic toe pressure (IP_STP). Numbers of patients at risk entering intervals are shown at bottom. P
values significant in pairwise comparison are shown in color corresponding to compared curve.
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Volume 70, Number 6Data collection and statistical analysis. The primary
end point for the study was death for any reason. The
secondary end point was death due to cardiovascular
reasons, defined as any International Classification of
Diseases, Tenth Revision-coded immediate cause of
death between I00 and I42.5 and I42.7 and I99. Dates
and causes of death were obtained from Statistics
Finland. Demographic patient data were retrospectively
collected from the hospital electronic database. Baseline
characteristics at the time of DSA, which served as the
index date for follow-up, were used. International Clas-
sification of Diseases, Tenth Revision-coded diagnoses
were registered. Risk factors collected for analysis
included coronary artery disease, cerebrovascular dis-
ease, hypertension, current smoking, diabetes, sleep
apnea, chronic obstructive pulmonary disease, end-stage
renal disease, dyslipidemia, SAP, ABI, STP, TBI, and serumcreatinine concentration. Baseline medication including
statins, clopidogrel, aspirin, warfarin, and novel antico-
agulants was registered from within electronic patient
files. For the purpose of analysis, toe pressure was pooled
into three categories (<30 mm Hg, 30-49 mm Hg, and
$50 mm Hg [reference]), and TBI was pooled into three
categories (<0.25, 0.25-0.49, and $0.50 [reference]).
Contralateral and ipsilateral limb pressures were
analyzed separately as described before.
All statistical analyses were performed using SPSS
version 25 (IBM, Armonk, NY) with R statistics extension.
Group-specific baseline characteristics were presented
as percentages and continuous variables as mean 6
standard deviation (SD). Group variables were compared
using Fisher exact test. Normality of distribution for
continuous variables was tested with a Shapiro-Wilk
test. Variables were then compared by analysis of
Table III. Association between systolic toe pressure (STP) and toe-brachial index (TBI) of contralateral and ipsilateral lower
extremity with cardiovascular and overall mortality in multivariable analysis
STP HR 95% CI P value TBI HR 95% CI P value
Cardiovascular
mortality
Age 1.018 1.01-1.06 .05 Cardiovascular
mortality
Age 1.017 1.00-1.03 .12
CAD 1346 1.02-1.77 .35 CAD 1.365 1.04-1.80 .27
HT 1318 0.957-1.82 .91 HT 1.284 0.932-1.77 1.00
DM 1.222 0.920-1.63 1.00 DM 1.228 0.923-1.63 1.00
Renal
insufficiency
1.461 0.992-2.15 .55 Renal
insufficiency
1.443 0.980-2.13 .63
Statin use 0.734 0.549-0.982 .38 Statin use 0.738 0.551-0.988 .41
Smoking history 0.466 0.320-0.678 <.001 Smoking history 0.463 0.318-0.674 <.001
STP contralateral limb TBI contralateral limb
$50 mm Hg Reference $0.50 Reference
30-49 mm Hg 1.928 1.38-2.68 <.001 0.25-0.49 1.549 1.14-2.10 .05





Age 1.019 1.01-1.02 .08 Age 1.018 1.01-1.03 .08
CAD 1.403 1.06-1.87 .20 CAD 1.428 1.07-1.90 .14
HT 1.199 0.860-1.67 1.00 HT 1.140 0.819-1.59 1.00
DM 1.279 0.954-1.72 1.00 DM 1.242 0.926-1.67 1.00
Renal
insufficiency
1.656 1.10-2.49 .15 Renal
insufficiency
1.531 1.03-2.29 .37
Statin use 0.738 0.547-0.994 .45 Statin use 0.771 0.573-1.04 .87
Smoking history 0.486 0.333-0.708 <.001 Smoking history 0.474 0.325-0.691 <.001
STP ipsilateral limb TBI ipsilateral limb
$50 mm Hg Reference $0.50 Reference
30-49 mm Hg 1.642 1.11-2.43 .13 0.25-0.49 1.981 1.08-3.63 .27







Age 1.020 1.01-1.03 <.001 Overall
mortality
Age 1.018 1.01-1.03 <.001
CAD 1.116 0.900-1.38 1.00 CAD 1.125 0.908-1.39 1.00
HT 1.219 0.956-1.56 1.00 HT 1.185 0.929-1.51 1.00
DM 1.042 0.834-1.30 1.00 DM 1.049 0.838-1.31 1.00
Renal
insufficiency
2.118 1.55-1.14 .05 Renal
insufficiency
1.515 1.11-2.07 .09
Statin use 0.740 0.590-0.929 .09 Statin use 0.743 0.592-0.933 .10
Smoking history 0.568 0.434-0.743 <0.001 Smoking history 0.567 0.434-0.741 <0.001
STP contralateral limb TBI contralateral limb
$50 mm Hg Reference $0.50 Reference
30-49 mm Hg 1.788 1.38-2.32 <.001 0.25-0.49 1.624 1.29-2.05 <.001





Age 1.019 1.01-1.03 <.001 Age 1.020 1.01-1.03 <.001
CAD 1.156 0.926-1.44 1.00 CAD 1.172 0.939-1.46 1.00
HT 1.150 0.893-1.48 1.00 HT 1.106 0.859-1.42 1.00
DM 1.076 0.855-1.36 1.00 DM 1.052 0.835-1.33 1.00
Renal
insufficiency
1.714 1.24-2.37 .01 Renal
insufficiency
1.620 1.18-2.23 .03
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Table III. Continued.
STP HR 95% CI P value TBI HR 95% CI P value
Statin use 0.745 0.590-0.940 .13 Statin use 0.774 0.613-0.977 .31
Smoking history 0.569 0.433-0.748 <.001 Smoking history 0.552 0.419-0.726 <.001
STP ipsilateral limb TBI ipsilateral limb
$50 mm Hg Reference $0.50 Reference
30-49 mm Hg 1.468 1.10-1.96 .09 0.25-0.49 2.011 1.29-3.15 .02





CAD, Coronary artery disease; CI, confidence interval; DM, diabetes; HR, hazard ratio; HT, hypertension; SD, standard deviation.
Reference $50 mm Hg for STP and $0.50 for TBI categories. Confounding factors forced into Cox regression analysis were selected according to
significance in univariate analysis. Age: HR per 1-year increase.
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mally distributed.
Survival was assessed by Kaplan-Meier and log-rank sta-
tistics. A Cox regression analysis was performed to assess
the final predictive value of factors associated with sur-
vival. Factors with P < .2 in univariate analysis were forced
into a Cox proportional hazards model. Multivariable
analysis was carried out to assess the risk of death. To
reduce the probability of false-positive observations,
P values were Bonferroni adjusted for multiple expo-
sures. P < .05 was considered statistically significant.
RESULTS
Standardized peripheral pressure measurementsd
SAP, STP, or bothdwere available for 732 patients. STP
and TBI of either lower extremity were available for 727
patients and for both extremities of 699 patients; 28
patients had undergone previous amputation or had
extensive tissue loss in the foot (Fig 1).
Demographic factors by corresponding CL_STP cate-
gories (727 patients) for the study cohort are shown in
Table I. Risk factors did not significantly differ between
CL_STP categories, with the exception of diabetes and
smoking history. There were more diabetics and less
ever-smokers with decreasing CL_STP. The proportion
of patients who eventually did not receive invasive treat-
ment also differed significantly between groups, with an
increasing percentage of patients treated conservatively
(17.7% of all cases) as CL_STP decreased. Of all cases,
59.7% underwent at least one endovascular revasculari-
zation, 37.4% at least one surgical revascularization, and
14.9% at least one hybrid revascularization during
follow-up.
Causes of death. Median follow-up time was
55.5 months for the whole study cohort and 67.0 months
for survivors. At 7 years, 347 patients (48%) had died.
Cardiovascular causes of death were most common,
accounting for 210 (61%) deaths. Cardiovascular causes of
death were significantly (P < .001) more common among
patients with CL_STP <30 mm Hg (71%) compared withthose with higher CL_STP. Furthermore, patients with
CL_STP <30 mm Hg died more frequently of reasons
associated with dementia (Table II).
STP and mortality. Estimated freedom from cardiovas-
cular death and overall survival at 60 months was signif-
icantly better in patients with CL_STP $50 mm Hg (75%
[SD, 0.46] and 60% [SD, 0.46], respectively) compared
with other CL_STP categories (P < .001). Freedom from
cardiovascular death and overall survival differed signifi-
cantly between all ipsilateral STP (IP_STP) categories
(P < .001-.003; Fig 2).
In multivariable analysis, the risk of all-cause death and
cardiovascular death increased significantly with
CL_STP <30 mm Hg and 30 to 49 mm Hg (P < .001)
compared with CL_STP $50 mm Hg. IP_STP <30 mm
Hg but not 30 to 49 mm Hg significantly increased
(P < .001) the risk of both cardiovascular and overall mor-
tality compared with IP_STP $50 mm Hg (Table III).
Estimated freedom from cardiovascular death
(P ¼ .005) and overall survival (P ¼ .002) of patients
with IP_STP <30 mm Hg and CL_STP $50 mm Hg
(62% [SD, 0.52] and 47% [SD, 0.52], respectively) were
significantly better compared with those with
STP <30 mm Hg bilaterally (41% [SD, 0.58] and 25%
[SD, 0.43], respectively). Overall survival of patients with
IP_STP of 30 to 49 mm Hg and CL_STP $50 mm Hg
(57% [SD, 0.52]) was significantly better compared with
those with CL_STP of 30 to 49 mm Hg (38% [SD, 0.47];
P ¼ .014; Fig 3).
TBI and mortality. Estimated freedom from cardiovas-
cular death at 60 months differed significantly between
all CL_TBI categories (P < .001-.001), and overall survival
was significantly higher for CL_TBI $0.50 (65% [SD,
0.58]) compared with lower TBI categories (P < .001).
All ipsilateral TBI (IP_TBI) categories differed significantly
with respect to freedom from cardiovascular death and
overall survival (P < .001-.013; Fig 4).
In multivariable analysis, the risk of all-cause death
and cardiovascular death increased significantly with
Fig 3. Kaplan-Meier survival curves showing freedom from cardiovascular death (A-C) and overall survival (D-F) by
contralateral systolic toe pressure (CL_STP) for patients with ipsilateral systolic toe pressure (IP_STP) <30 mm Hg
(A and D), 30 to 49 mmHg (B and E), and$50mmHg (C and F). Numbers of patients at risk entering intervals are
shown at bottom. P values significant in pairwise comparison are shown in color corresponding to compared curve.
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significantly (P < .001) increased the risk of both cardio-
vascular and overall mortality (Table III).
Estimated freedom from cardiovascular death and
overall survival of patients at defined IP_TBI categories
at 60 months differed further by CL_TBI. Freedom from
cardiovascular death of patients with IP_TBI <0.25 and
CL_TBI $0.50 (64% [SD, 0.53]) was significantly higher
compared with those with CL_TBI <0.25 (49% [SD,
0.57]; P < .038), and both freedom from cardiovascular
death (P ¼ .018) and overall survival (P < .001) of patients
with IP_TBI of 0.25 to 0.49 and CL_TBI $0.50 (80% [SD,
0.42] and 67% [SD, 0.42], respectively) were significantly
higher compared with patients with CL_TBI of 0.25 to
0.49 (66% [SD, 0.50] and 44% [SD, 0.50], respectively).
CL_TBI had no significant effect on overall survival in
patients with IP_ TBI <0.25 (Fig 5).
DISCUSSION
The study delineated the association of STP and TBI of
the contralateral lower extremity with long-term mortal-
ity in 727 symptomatic PAD patients. Low CL_STP andCL_TBI were both associated with high mortality. Patient
outcome also differed significantly between high and
low CL_STP within the group of patients with low IP_STP.
A linear time- and pressure-dependent association with
regard to both cardiovascular and overall mortality was
observed for both CL_STP and IP_STP.
An increased rate of adverse cardiovascular events and
overall mortality with both abnormally high and low ABI
has been demonstrated in previous large population
studies and investigations.6,28 This relationship is U
shaped because comorbidities such as diabetes and
end-stage renal disease render distal leg arteries incom-
pressible.15,16 Patients with symptomatic PAD and ABI
> 1.3, with and without diabetes, have increased amputa-
tion rates.29 Although there is a strong body of evidence
on both low and pathologically high ABI yielding an
increased risk for adverse cardiovascular events and
death, studies regarding the association of STP, TBI, and
patient outcome are scarce, with some reports demon-
strating that TBI is prognostic for cardiovascular mortality
and morbidity.16,30 This study, with >700 patients with
STP and TBI measurements, shows a linear correlation
Fig 4. Kaplan-Meier survival curves showing freedom from cardiovascular death (A) and overall survival (B) by
contralateral toe-brachial index (CL_TBI) and freedom from cardiovascular death (C) and overall survival (D) by
ipsilateral toe-brachial index (IP_TBI). Numbers of patients at risk entering intervals are shown at bottom. P values
significant in pairwise comparison are shown in color corresponding to compared curve.
Journal of Vascular Surgery Wickström et al 2001
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all mortality. The data further suggest that CL_STP and
CL_TBI are associated with patient outcome, stratifying
patients with similar IP_STP or IP_TBI.
According to these data, CL_STP <50 mm Hg and
CL_STP <30 mm Hg in particular are significantly associ-
ated with poor patient outcome. Cutoff values for STP for
this study were selected according to generally accepted
criteria for CLTI.31-33 It is generally accepted that CLTI is
associated with poor patient outcome,28,34 and our
results further support the notion of CLTI’s having a
malignant nature. The role of TBI in evaluating the
severity of PAD is largely undefined. Previous guidelines
recommend <0.70 as a cutoff between pathologic and
normal TBI, but this cutoff is not evidence based.35 There
are no data confirming the utility of TBI in early detection
of PAD among diabetics. The results of a Dutch studysuggest that diabetes may indeed falsify both ABI
and TBI.20
Low STP values are associated with a high risk of ampu-
tation.36-38 We have previously observed a strong associa-
tion between IP_STP and midterm cardiovascular and
overall mortality as well as amputation-free survival.
Similar results for all-cause mortality have been reported
earlier in a study including 76 limbs in 53 patients.37 Our
study analyzes STP and TBI measurements for both
lower limbs in 699 patients. STPs fulfilling CLTI criteria
for the symptomatic limb were observed in 227 patients
(TP <30 mm Hg) and TBI in 267 patients (TBI <0.25).
Although recent guidelines consider ABI a principal
tool for cardiovascular risk stratification, our findings sup-
port the use of both STP and TBI as powerful noninvasive
tools for detecting patients at highest risk of death,
notably from cardiovascular events, in need of aggressive
Fig 5. Kaplan-Meier survival curves showing freedom from cardiovascular death (A-C) and overall survival (D-F) by
contralateral toe-brachial index (CL_TBI) for patients with ipsilateral toe-brachial index (IP_TBI) <0.25 (A and D),
0.25 to 0.49 (B and E), and $0.50 (C and F). Numbers of patients at risk entering intervals are shown at bottom.
P values significant in pairwise comparison are shown in color corresponding to compared curve.
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ments are available at a general practitioner’s office.35
They may provide an alternative tool to ABI for screening
high-risk patients at diabetes outpatient clinics because
of a linear risk stratification. CL_STP and CL_TBI might
serve as a valuable tool for comprehensive noninvasive
risk stratification, even among CLTI patients. This study
emphasizes the importance of bilateral pressure mea-
surements in all PAD patients.
All patients included in the study had symptomatic
(Rutherford category 2-6) PAD and were referred to
DSA by a vascular specialist. DSA, at the time of the study,
was the primary imaging modality for any such patient
with an accessible femoral artery. The cohort does not
include individuals who do not primarily fulfill criteria
for invasive treatment. Randomly selected age- and risk
factor-matched nonsymptomatic individuals were not
available as a reference group. Even so, the study popula-
tion is large, and it contains peripheral pressure measure-
ments from patients irrespective of their diabetic status
or PAD history. Because of these delineations, the results
should further support the use of STP and TBI for cardio-
vascular risk evaluation in everyday clinical practice.CONCLUSIONS
The U-shaped association of ABI with cardiovascular
morbidity and mortality has been well documented,
and ABI has been shown to be a potent noninvasive
tool in PAD screening. In many vascular units, SAP, ABI,
STP, and TBI are first-line investigations for clinical
decision-making and routinely used in everyday practice.
Although STP is rarely affected by incompressible digital
arteries, it has been shown to be sensitive to changes in
skin temperature and patient comorbidities, and it is de-
vice dependent.22,39 To minimize the influence of these
confounding factors on results, only standardized
vascular laboratory pressure measurements were
accepted into this study.
With a recent emergence of particularly aggressive
medical therapies showing promise of decreased cardio-
vascular mortality in PAD patients, identifying those
patients at highest risk of cardiovascular death may
allow targeting them with novel treatment regimens.
Statin therapy at moderate doses is generally considered
safe and effective in lowering the risk of cardiovascular
events in patients with PAD.40 High-dose statin therapy
reduces this risk even further, but concerns about
Journal of Vascular Surgery Wickström et al 2003
Volume 70, Number 6potentially serious adverse effects of high-dose statin
therapy have been raised, and it has been proposed
that this treatment should be reserved for those PAD
patients at highest risk for cardiovascular death. With
emerging novel lipid-lowering and antithrombotic thera-
pies showing promise of even further risk reduction, justi-
fying the risk of treatment-related adverse events in light
of the sinister prognosis of patients at greatest risk of
cardiovascular death may become increasingly impor-
tant.41,42 Based on our observations, noninvasive mea-
surement of STP and TBI of both lower extremities is
linearly prognostic of long-term cardiovascular and over-
all survival in symptomatic PAD patients, with low STP
and TBI in the contralateral limb having an additive
effect on long-term mortality. Therefore, they provide a
valuable means to identify patients with highest cardio-
vascular mortality.
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